Cell And Gene Therapy Clinical Trials Market
Report ID: SQMIG35H2480
Report ID: SQMIG35H2480
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2480 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
116
|Figures:
72
Global Cell And Gene Therapy Clinical Trials Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).
The cell and gene therapy clinical trials market is primarily driven by rapidly advancing science that has transformed theoretical molecular therapies into proven clinical therapies. In addition, clinical trials in this market involve the testing of living cells (e.g., stem cells) or genetic (i.e., DNA), both of which are used to cure or prevent disease rather than managing the symptoms of a condition in a chronic manner, making the work in this area significant because it addresses significant unmet medical need in the fields of oncology, rare genetic disorders and immunology. The field has evolved over the years as evidenced by the span of time from early somatic gene therapy trials through the approval of the first gene therapies (e.g., Luxturna to treat inherited retinal dystrophy) and commercially available CAR T-cell therapies (e.g., Kymriah) that have changed the way investors, rigorous regulatory environments and trial designs operate throughout the globe.
A primary factor influencing the global cell and gene therapy clinical trials market growth is the progress that has occurred with scaling up the manufacturing of these products, as the maturation of supply chains associated with the reliable manufacture of such products decreases previous time and cost limits restricting the growth of clinical trials. The development of consistent vector yields and standardized processing methods for cellular products allows manufacturers to produce increased quantities of study/clinical product to be used in multicenter studies, enabling the pursuit of route/frequency of administration for allogeneic and in-vivo products at predictable levels of quality, as such, establishing an extremely wide array of study product indications from oncology through hematology. Therefore, this increasing level of strategic collaboration and partnering among biopharmaceutical companies, contract development and manufacturing organizations, and hospitals for example, is evidenced by the continuing development of multiple partnerships among pharmaceutical companies and contract manufacturers to develop CAR T-cell therapies and AAV products, leading to increased venture and corporate financing for biopharmaceutical "disruptive" technologies that will accelerate enrollment into clinical studies while enhancing the economic possibilities for the global commercial adoption of cell and gene therapies.
How is AI Optimizing Patient Selection In The Cell And Gene Therapy Clinical Trials Market?
By integrating multimodal data, including genomic profiles, single-cell information, medical imaging, and electronic health records, AI is revolutionizing the method for determining eligibility for patient selection in the cell and gene therapy clinical trials market. Machine learning is now employed to identify biomarker-driven sub-groups, predict responders, and automate eligibility assessments, all of which support a far faster means of manual review. This is crucial in an environment where individualised therapies are faced with complex inclusion criteria and manufacturing limitations. For example, AI has the ability to interpret single-cell signature data and natural language processing to extract detailed clinical histories to provide more accurate patient cohorts and more predictable enrolment.
Deepcell entered a partnership with InGel Therapeutics in September 2025 to utilise AI-based single-cell analysis to develop ocular cell therapies. Such innovations in patient stratification during the manufacturing of ocular cell therapies will improve the quality of the final product, thereby providing faster enrolment, improved trial efficiencies, and better market scalability.
Market snapshot - (2026-2033)
Global Market Size
USD 8.52 Billion
Largest Segment
Cell Therapy
Fastest Growth
Gene Therapy
Growth Rate
14.52% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global cell and gene therapy clinical trials market is segmented by therapy type, phase, indication, end-user and region. Based on therapy type, the market is segmented into Cell Therapy and Gene Therapy. Based on phase, the market is segmented into Phase I, Phase II and Phase III. Based on indication, the market is segmented into Oncology, Rare Diseases and Neurological. Based on end-user, the market is segmented into CROs, Academic Medical Centers and Pharma & Biotech. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per global cell and gene therapy clinical trials market analysis, the CROs is the leading segment because CROs provide the specific functionality and the end-to-end, comprehensive trial management support needed for complex cell and gene therapy trial protocols. The consolidated manufacturing partner relationships, logistics experience (Cold Chain and custom products), and the regulatory/sited network experience that the CRO possesses, all reduce operational friction for the Sponsor. Therefore, this operational competency facilitates the rapid execution of trial protocols and efficaciously supports a larger number of trial portfolios across various modalities resulting in sustained leadership in that segment.
As per global cell and gene therapy clinical trials market forecast, the most rapidly expanding end user for clinical research is the Academic Medical Center. The concentration of patient populations in their studies, combined with their translational research and ability to perform investigator initiated trials, enables them to perform first-in-human testing. In combination with their integrated clinical infrastructure provides a mechanism for adaptive clinical trial designs, biomarker-driven patient recruitment opportunities, and the ability to provide evidence to support follow-on therapy development, attracts this type of partnering relationship and enables the generation of the initial evidence required to provide a basis for new indications and, subsequently, catalyze future long-term commercial development.
As per global cell and gene therapy clinical trials market outlook, the oncology segment leads the way because there has been significant investment and proof of concept to drive the immunotherapy sector. With many possible targetable antigens, well-established surrogate endpoints, and viable patient cohorts available to enroll in studies in advanced disease settings, rapid innovation in protocol design will occur. With a substantial industry focus on combining immunotherapies, developing translational biomarkers, and ensuring commercial viability through the research process, trial volume and resources will be allocated to cancer programs.
Meanwhile, rare disease studies are the fastest growing area in research due to the use of targeted therapies, commercial incentives to develop new treatments for orphan indications, and the use of precise gene editing to create targeted protocols with a solid mechanistic rationale. These types of therapies offer several advantages to sponsors, including a streamlined regulatory engagement and creating new avenues for increased trial innovation.
To get detailed segments analysis, Request a Free Sample Report
As per global cell and gene therapy clinical trials market regional outlook, by having the required concentration of scientific expertise and state-of-the-art infrastructure for clinical research, North America holds position as a world leader in the conduct of clinical trials through its extensive, interconnected and cooperative networks of academic institutions, biotechnology companies and specialized Contract Research Organizations ("CROs"). Access to established regulatory pathways that support the ongoing development of new products will continue to enable the efficient design of clinical trials, the prompt and efficient development of new products, and the timely access by patients to these products as a result of clear guidance from the product approval process. Manufacturers have made significant investments in translational research and at both the individual and institutional levels in high-capacity manufacturing facilities, which will facilitate the transfer of complex cell and gene therapy products from early to late development. A wealth of experienced clinical investigators, coupled with established patient registries, enhances the ability to recruit patients with rare and niche conditions. The formation of strategic partnerships between industry and academic centers will accelerate the development of optimal protocols and the scale-up of the manufacturing process. Together, these factors are helping to maintain North America's leadership position and global dominance in the number of clinical trials conducted and the diversity of therapeutic products available for patients.
A concentration of centers of excellence, extensive clinical trial networks, and integrated manufacturing systems within the United States have all contributed to the success of the cell and gene therapy clinical trials market. In addition to the presence of major biotechnology companies and specialized CROs, is the increasing rate of translational activities due to there being a collaborative culture between sectors, access to experienced investigators and established patient referral systems to help recruit patients for advanced therapies and continue trials across multiple sites.
In Canada, the cell and gene therapy clinical trials market has developed due in large part to the collaborative networks of academia, supportive infrastructure for clinical trials, and the increasing manufacturing capability that allows for early stage and complex studies. A unique regulatory environment along with strong public-private partnerships and supportive policy frameworks enable clinical coordination of their protocols and ultimately improve the implementation of those protocols. Furthermore, due to the proximity of specialized research hospitals to each other and the emphasis on patient-centered design of clinical trials; patient recruitment for innovative therapies is more efficient thereby increasing the likelihood of cross-border collaboration between the two development hubs.
As per global cell and gene therapy clinical trials market regional analysis, Europe has been growing rapidly, with innovation thriving both on its own and through cooperation between numerous specialized research institutions, a rapidly growing number of biotechnology companies and coordinated clinical networks that cross national borders. The development of new regulatory frameworks and pathways to regulate the advanced therapies will provide clearer routes to approve trials and conduct multi-centre collaborations. The development of strong public funding mechanisms and public-private partnerships has made improvements to translational pipelines and the infrastructure required for clinical manufacturing. There are many different populations of patients and there are many established academic hospitals that can act as sources for recruitment of patients for various types of therapies. Cross-border initiatives and harmonized guidelines have allowed for the implementation of protocols across multiple regions, while key market centres in Europe are expanding their capabilities to expedite trial readiness and increase regional capacity for cell and gene therapy studies with a high level of complexity. Behind this cooperative environment are experts from across all sectors, including manufacturing, clinical operations and biomarker development who can work together on the design of more innovative trials and implement adaptive designs.
The Germany cell and gene therapy clinical trials market is growing quickly because of collaborative relationships between Universities & Manufacturers. National Policies to support "Advanced Therapies" will create the necessary infrastructure for Developing and implementing multicenter trials. There is a concentration of specialized hospitals and technical expertise in Germany that allow for Managing about Protocol Complexity & Enrolling Patients with novel modalities. These factors are combining to make Germany one of the top places to Grow within the European clinical trial ecosystem for cell & gene therapies
The UK cell and gene therapy clinical trials market is attracting attention for its established Research Institutions, a highly developed Regulatory Environment, and the strength of the Networking among the Hospitals and Commercial Developers. Concentration of clinical Trial management capabilities and Access To Specialized Facilities are making it easier to conduct Complex Studies. With established Translational Pathways and collaboration between Academic Institutions and the Biotech Industry, providers are Developing New Protocols and Recruiting Patients in the UK as a hub for Advanced Therapy Work.
The French cell and gene therapy clinical trials market continues to grow through increased funding for translating research, expanding the capacity of clinical manufacturing, and connecting research hospitals with industry. A focus on networks of patient care and clinical units will support the recruitment of patients into new modalities. Policy support and collaborative processes are facilitating trial design that is more sophisticated and enabling a greater number of complex studies; thus, France is an emerging participant in the regional advanced therapeutics market.
Through coordinated investments in clinical research infrastructure; targeted policy updates to simplify advanced therapy pathways; and enhanced clinical manufacturing capabilities; Asia Pacific is strengthening its position as a leader in cell & gene therapy innovation. While local contract research organisations (CROs) and contract manufacturing organisations (CMOs) are growing their capabilities to handle cells and produce vectors, established centres of excellence and major academic hospitals are bolstering their capacity to execute complex studies. In addition, local and international biotechnology companies are forming strategic partnerships that are accelerating the transfer of knowledge and the sophistication of study design across the region. Ongoing commitment to patient registries, biomarker development and investigator training will continue to contribute to improved recruitment and quality of clinical studies. The culmination of these efforts is creating a more integrated ecosystem that will facilitate the translation of cell and gene therapy innovations across all major markets in the Asia Pacific region. Major regulatory agencies throughout the region are continuing to improve clarity regarding the requirements to conduct clinical studies and offer incentives to promote the development of products domestically; this will continue to encourage sponsors to develop multilateral clinical trials based in the Asia Pacific region.
The Japan cell and gene therapy clinical trials sector continues to grow through investments in translational research, hospitals with the capability to deliver complex protocols, and increased cell and vector manufacturing capability. Increased regulatory engagement clarified approval pathways and supported innovative trial design, leading to increased operational predictability. The partnership between local developers and international developers provides an opportunity for knowledge sharing and multi-regional studies; therefore, Japan will become a development hub for the Asia Pacific region.
The South Korea cell and gene therapy clinical trials market continues to develop as a result of the expansion of the biotechnology industry, investments in clinical manufacturing, and training initiatives to prepare investigators for advanced protocols. Networks connecting academic medical centres to industry partners improve the efficiency of trial execution and patient recruitment for specialized indications. Collaboration with global sponsors facilitates access to new technologies and adoption of innovative studies, making South Korea an important player in the regional market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Innovations In Gene Delivery
Advancements in vector development and delivery methods, along with new formulations, have improved the ability to accurately direct cells to the desired location, limit unwanted effects on other cells, increase confidence in the manufacturing process and broaden the number of areas of application for gene and cell therapy products. Furthermore, these innovations have provided simpler methods for dosing and improving the reliability of the manufactured products which will lead to more efficient protocols and greater patient recruitment rates for clinical trials. Advances in manufacturing and stability of the therapeutic agents also reduce operational barriers for sponsors thereby increasing the number of clinical trials and expanding the number of areas in which they will conduct clinical studies.
Expanding Regulatory Support Frameworks
Complex Manufacturing and Scalability
The difficult nature of producing autologous and allogeneic cell products as well as meeting high standards for quality control and the requirement for a proper cold-chain to maintain product quality presents challenges that limit the number of clinical studies that can be conducted per year and affect the pace of clinical studies conducted. These manufacturing constraints necessitate obtaining specialized facilities, validated manufacturing processes and trained personnel to maintain the consistency and safety of cell products, thus creating additional logistical and lead-time issues. Therefore, sponsors have difficulty rapidly increasing the number of trial participants enrolled in trials across multiple sites, which creates increased operational risk for sponsors and slows the rate of trial approvals overall.
High Cost and Reimbursement Uncertainty
Request Free Customization of this report to help us to meet your business objectives.
The cell and gene therapy clinical trials sector is highly competitive and focused on strategic mergers and acquisitions, specialty licensing partnerships, and innovative platforms that accelerate regulatory approval processes or enable larger manufacturing capacity than previously available. In recent months, significant examples of moves that have taken place include Eli Lilly’s purchase of Verve Therapeutics, Graphite Bio’s merger with LENZ, and many early stage companies completing their first round of venture capital financing and forming partnerships with venture studios in order to facilitate the further development of their phase 2 programs. All of these examples exhibit the level of competition taking place in this field based on the completion of deals.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global cell and gene therapy clinical trials market is driven by transformational scientific breakthroughs that have turned molecular interventions into reproducible clinical successes, and further supported by scalable manufacturing and supply chain maturation which enables broader multicenter studies. Growth is restrained by complex manufacturing and scalability challenges that increase costs and operational bottlenecks. North America remains the dominant region due to concentrated expertise, infrastructure and regulatory support, while oncology is the leading segment as cancer applications attract the most trials and investment. Continued platform diversification and regulatory harmonization should sustain expansion but sponsors must address production and reimbursement hurdles to fully realize market potential.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 8.52 Billion |
| Market size value in 2033 | USD 28.85 Billion |
| Growth Rate | 14.52% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cell And Gene Therapy Clinical Trials Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cell And Gene Therapy Clinical Trials Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cell And Gene Therapy Clinical Trials Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cell And Gene Therapy Clinical Trials Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Cell And Gene Therapy Clinical Trials Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).
Competitive dynamics in the global cell and gene therapy clinical trials market are concentrated around strategic M&A, targeted licensing alliances and platform innovation that speed regulatory paths and manufacturing scale. Recent, concrete moves include Eli Lilly's acquisition of Verve Therapeutics, Graphite Bio's merger with LENZ and multiple startups closing Series A rounds and partnering with venture studios to advance Phase 2 programs, illustrating deal driven competition. 'Novartis AG (Kymriah)', 'Gilead Sciences (Yescarta)', 'Bristol Myers Squibb (Abecma)', 'bluebird bio', 'Spark Therapeutics (Roche)', 'uniQure NV', 'Sarepta Therapeutics', 'Fate Therapeutics', 'Allogene Therapeutics', 'Celgene (BMS)', 'Arcus Biosciences', 'Marker Therapeutics', 'Iovance Biotherapeutics', 'Cellular Biomedicine Group', 'Lonza Group'
Innovations in vector design, delivery platforms, and formulation techniques have improved the ability to target cells precisely and reduce off-target effects, which increases clinical confidence and expands potential indications for cell and gene therapies. These technical advances also simplify dosing strategies and enhance product consistency, making protocol development and patient recruitment more predictable. Improved manufacturability and stability of therapeutic constructs lower operational barriers for sponsors, encouraging more trials and broader investigational programs across diverse therapeutic areas.
Platform Diversification Accelerates Growth: Developers are expanding vector and cell platforms to broaden therapeutic reach and reduce reliance on single-approach pipelines. This diversification fosters strategic partnerships, and modular process development that support flexible trial designs and faster translation of research into clinical protocols. Sponsors prioritize adaptable platform stacks to address diverse indications, optimize patient enrollment strategies, and mitigate program-level risk while preserving regulatory alignment. The trend encourages ecosystem growth, attracts specialized service providers, and enhances long-term portfolio resilience across evolving scientific and commercial landscapes.
Why does North America Dominate the Global Cell And Gene Therapy Clinical Trials Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
